Advanced Search

Technical Analysis for LABP - Landos Biopharma, Inc.

Grade Last Price % Change Price Change
F 10.67 0.66% 0.07
LABP closed up 0.66 percent on Wednesday, May 5, 2021, on 14 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical LABP trend table...
Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Fell Below 20 DMA Bearish 0.66%
NR7 Range Contraction 0.66%
Down 3 Days in a Row Weakness 0.66%
Down 4 Days in a Row Weakness 0.66%
Down 5 Days in a Row Weakness 0.66%
20 DMA Support Bullish -3.09%
Older End-of-Day Signals for LABP ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible Inside Day about 7 hours ago
Possible NR7 about 7 hours ago
Up 2% about 11 hours ago
Up 1% about 11 hours ago
Possible NR7 1 day ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators Basic chart:

Profile

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and inflammatory bowel diseases. The company also develops NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1, a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and PX-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and rheumatoid arthritis. The company was founded in 2017 and is headquartered in Blacksburg, Virginia.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Autoimmune Diseases Rheumatoid Arthritis Inflammatory Bowel Disease Gastroenterology Colitis Ulcerative Colitis Abdominal Pain Diarrhea Crohn's Disease Diabetic Nephropathy Inflammatory Bowel Diseases

Is LABP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date Title
May 4 Is Landos Biopharma (NASDAQ:LABP) In A Good Position To Invest In Growth?
Apr 29 Landos Biopharma Announces First Patient Dosed in a Phase 1b Study of NX-13 for Ulcerative Colitis
Apr 26 Raymond James: These 3 Stocks Have Over 100% Upside on the Horizon
Apr 26 Landos Biopharma to Present Two Late-Breaking Presentations on Therapeutic Potential of Omilancor and PX-69 at the 2021 American Association of Immunologists (AAI) Annual Meeting
Apr 13 Landos Biopharma Announces the Appointment of Tiago Girão to its Board of Directors
Apr 6 Landos Biopharma Stock Is Trading Higher On Initiating Early-Stage Study With Omilancor For Esophagus Inflammation
Apr 6 Landos Biopharma Announces FDA Clearance of IND Application for Omilancor for the Treatment of Eosinophilic Esophagitis
Mar 4 Landos announces positive Phase 1 results in inflammatory bowel disease
Mar 4 Landos Biopharma Announces Positive Results from a Phase 1 Study of NX-13 in Healthy Volunteers
Feb 27 The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings
See more LABP news...

Indicators

Indicator Value
52 Week High 16.989
52 Week Low 8.84
Average Volume 143,195
200-Day Moving Average 0.00
50-Day Moving Average 11.84
20-Day Moving Average 10.87
10-Day Moving Average 11.07
Average True Range 0.85
ADX 13.66
+DI 18.08
-DI 20.18
Chandelier Exit (Long, 3 ATRs ) 9.59
Chandelier Exit (Short, 3 ATRs ) 11.87
Upper Bollinger Band 12.06
Lower Bollinger Band 9.68
Percent B (%b) 0.42
BandWidth 21.90
MACD Line -0.13
MACD Signal Line -0.19
MACD Histogram 0.0579
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.14
Resistance 3 (R3) 11.14 10.98 11.06
Resistance 2 (R2) 10.98 10.86 10.98 11.04
Resistance 1 (R1) 10.82 10.78 10.90 10.83 11.01
Pivot Point 10.66 10.66 10.70 10.66 10.66
Support 1 (S1) 10.51 10.54 10.59 10.51 10.33
Support 2 (S2) 10.35 10.47 10.35 10.30
Support 3 (S3) 10.19 10.35 10.28
Support 4 (S4) 10.20